Morgan T Sutton, David Fletcher, Nicole Episalla, Lauren Auster, Sukhmani Kaur, Mary Chandler Gwin, Michael Folz, Dante Velasquez, Varun Roy, Rolf van Heeckeren, Donald P Lennon, Arnold I Caplan, Tracey L Bonfield
{"title":"Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis.","authors":"Morgan T Sutton, David Fletcher, Nicole Episalla, Lauren Auster, Sukhmani Kaur, Mary Chandler Gwin, Michael Folz, Dante Velasquez, Varun Roy, Rolf van Heeckeren, Donald P Lennon, Arnold I Caplan, Tracey L Bonfield","doi":"10.4172/2157-7633.1000400","DOIUrl":null,"url":null,"abstract":"<p><p>Human Mesenchymal stem cells (hMSCs) secrete products (supernatants) that are anti-inflammatory and antimicrobial. We have previously shown that hMSCs decrease inflammation and <i>Pseudomonas aeruginosa</i> infection in the <i>in vivo</i> murine model of Cystic Fibrosis (CF). Cystic Fibrosis (CF) is a genetic disease in which pulmonary infection and inflammation becomes the major cause of morbidity and mortality. Our studies focus on determining how MSCs contribute to improved outcomes in the CF mouse model centering on how the MSCs impact the inflammatory response to pathogenic organisms. We hypothesize that MSCs secrete products that are anti-inflammatory in scenarios of chronic pulmonary infections using the murine model of infection and inflammation with a specific interest in <i>Pseudomonas aeruginosa</i> (gram negative). Further, our studies will identify whether the MSCs are impacting this inflammatory response through the regulation of peroxisome proliferator activator receptor gamma (PPARγ) which aides in decreasing inflammation.</p>","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":"7 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2157-7633.1000400","citationCount":"26","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of stem cell research & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2157-7633.1000400","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/9/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 26
Abstract
Human Mesenchymal stem cells (hMSCs) secrete products (supernatants) that are anti-inflammatory and antimicrobial. We have previously shown that hMSCs decrease inflammation and Pseudomonas aeruginosa infection in the in vivo murine model of Cystic Fibrosis (CF). Cystic Fibrosis (CF) is a genetic disease in which pulmonary infection and inflammation becomes the major cause of morbidity and mortality. Our studies focus on determining how MSCs contribute to improved outcomes in the CF mouse model centering on how the MSCs impact the inflammatory response to pathogenic organisms. We hypothesize that MSCs secrete products that are anti-inflammatory in scenarios of chronic pulmonary infections using the murine model of infection and inflammation with a specific interest in Pseudomonas aeruginosa (gram negative). Further, our studies will identify whether the MSCs are impacting this inflammatory response through the regulation of peroxisome proliferator activator receptor gamma (PPARγ) which aides in decreasing inflammation.